CALGARY, ALBERTA–(Marketwired – Feb. 2, 2016) – QuikFlo Health Inc. (“QuikFlo” or the “Company“) (TSX VENTURE:QF)(FRANKFURT:1QF) is pleased to announce that Dr. Andrew Demchuk, of Calgary, Alberta has joined its Advisory Board. Dr. Demchuk MD FRCPC is one of the founders of QuikFlo and is the Director of the Calgary Stroke Program located at the Foothills Medical Centre, and Deputy Chair of the Department of Clinical Neurosciences.
He is a Professor within the Departments of Clinical Neurosciences and Radiology at the University of Calgary. He holds the Heart and Stroke Foundation Chair in Stroke Research, and is current Deputy Chair of the Canadian Stroke Consortium.
He was a recipient of a Canada’s Top 40 Under 40 2008 award through Caldwell Partners and received the Canadian Stroke Network Paul Morley Stroke Mentorship Award in 2009.
Dr. Demchuk’s primary research interests are in the area of vascular imaging where he is trying to develop new treatments for stroke by optimally selecting patients based on transcranial Doppler, CT and MRI based imaging tests performed in the emergency setting. He is well published in the area of vascular imaging research as it pertains to stroke. His favourite pursuit is the training of stroke specialists through the Calgary Stroke Fellowship program. This program is training or has trained over 60 stroke fellows from 15 countries in the past 13 years.
Vinny Jindal, the Company’s President and CEO stated: “As the leader of the Calgary Stroke Program, which he has built into one of the premier stroke programs in the world, Dr. Demchuk has driven the science and clinical treatment of stroke forward not incrementally, but exponentially. He is regarded as one of the giants of the field, and for good reason. We are honored to have Dr. Demchuk join the QuikFlo Advisory Board.”
About QuikFlo
QuikFlo Health is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.
Further Information
For further information relating to the Company or this release please visit www.sedar.com, www.quikflohealth.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary and Forward-Looking Statements
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are currently reasonable, actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete suitable acquisitions to further the Company’s growth, the suitability of the key members of ongoing management and the board of directors, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on www.sedar.com. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive and additional risks and uncertainties are set forth in the circular.
No undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
